Measure | Description | Data Source | Measure aligns with interventions focused on: | Most rapid timeframe in which change might occur | Comments | |
---|---|---|---|---|---|---|
Members | Providers | |||||
Use of Appropriate Medications for People with Asthma (AQA and HEDIS Measure) | Percentage of members with persistent asthma who received at least one prescription for an appropriate medication in the measurement year |
|
√ | √ | 6-12 mos | This measure might be good to track in the short- to medium- term (6-18 mos). |
Daily Preventive Medication | Percentage of members with asthma who self-report the use of a controller medication |
|
√ | √ | 6 mos | Patient self-report goals can be a good way to obtain information about an intervention's effects in a short timeframe (< 6 mos). |
Written Action Plan | Percentage of members with asthma who have a personal action plan for managing their asthma |
|
√ | √ | 3-6 mos | If an intervention uses action plans, this measure could be effective. |
Self-Management Goal | Percentage of members with asthma who have a self-management goal |
|
√ | √ | 3-6 mos | Patient self-report goals can be a good way to obtain information about an intervention's effects in a short timeframe. |
Emergency Room (ER) Use | Percentage of members who visited the ER for asthma in the past 12 mos |
|
√ | √ | 12-18 mos | Reducing ER visits can exert a significant impact on cost and quality of life. |
Physician Followup Post-ER Visit or Post-Hospitalization | Percentage of members who followed up with a physician after an ER visit or hospital admission |
|
√ | √ | 12-18 mos | |
Influenza Vaccination | Percentage of all members with asthma who received a influenza vaccination within the past 12 mos |
|
√ | √ | 12-18 mos | Influenza vaccination can exert a significant impact on health care expenditures in members with asthma, particularly in epidemic years. The effect will, of course, be seasonal. |
HbA1c Screening (AQA and HEDIS Measure) | Percentage of members who received one or more HbA1c screenings in the measurement year |
|
√ | √ | 12 mos | Screening rates can be a good way to obtain information about an intervention's effects in a short timeframe. |
HbA1c Control(AQA and HEDIS Measure) | Percentage of members with diabetes with most recent LDL-C <130 mg/dl |
|
√ | √ | 12 mos | |
Low Density Lipoprotein Cholesterol (LDL-C) Screening (AQA and HEDIS Measure) | Percentage of members who received at least one LDL-C screening during the measurement year |
|
√ | √ | 12 mos | Screening rates can be a good way to obtain information about an intervention's effects in a short timeframe. |
LDL-C Level(<130mg/dl)(AQA Measure) | Percentage of members with diabetes with most recent LDL-C <130 mg/dl |
|
√ | √ | 12 mos | Seeing a change in clinical outcomes, such as cholesterol levels, might take a year or more. |
LDL-C Level (<100mg/dl) (AQA and HEDIS Measure) | Percentage of members with diabetes with most recent LDL-C <100 mg/dl |
|
√ | √ | 12 mos | Seeing a change in clinical outcomes, such as cholesterol levels, might take a year or more. |
Nephropathy Screening (HEDIS Measure) | Percentage of members with diabetes with a nephropathy screening or evidence of nephropathy |
|
√ | √ | 12 mos | Screening rates can be a good way to obtain information about an intervention's effects in a short timeframe. |
Eye Examination (AQA and HEDIS Measure) | Percentage of members who received one dilated retinal examination in the measurement year |
|
√ | √ | 12 mos | Screening rates can be a good way to obtain information about an intervention's effects in a short timeframe. |
Foot Examination | Percentage of members with diabetes who received at least one foot examination from a health care provider |
|
√ | √ | 12 mos | Screening rates can be a good way to obtain information about an intervention's effects in a short timeframe. |
Blood Pressure (AQA and HEDIS Measure) | Percentage of members with diabetes with most recent blood pressure <140/90 mm Hg |
|
√ | √ | 12 mos | Seeing a change in clinical outcomes, such as blood pressure, might take a year or more. |
ASA (aspirin)/Antiplatelet Therapy | Percentage of members with diabetes who were prescribed ASA/antiplatelet therapy |
|
√ | √ | 6 mos | |
Self-Management Goal | Percentage of members with diabetes who have a self-management goal |
|
√ | √ | 6 mos | Self-management goals can be useful in gauging patient activation. |
Influenza Vaccination | Percentage of all members with diabetes who received a influenza vaccination within the past 12 mos |
|
√ | √ | 12 mos | |
LDL-C Intensification | Percentage of members with diabetes with:
|
|
√ | √ | 12 mos | This measure represents a more sensitive "hybrid" indicator of change in provider behavior and improved quality of care. |
New York Heart Association (NYHA) Functional Classification | Percentage of members who have documentation of NYHA classification |
|
√ | 12 mos | ||
Blood Pressure | Percentage of members with congestive heart failure (CHF) with most recent blood pressure <140/80 mm Hg |
|
√ | √ | 12 mos | Seeing a change in clinical outcomes, such as blood pressure, might take a year or more. |
Beta Blocker Therapy after a Heart Attack (HEDIS) | Percentage of members who were discharged from a hospital for AMI and received persistent beta-blocker treatment for 6 mos after discharge |
|
√ | √ | 6-12 mos | This measure could be good for tracking in the short- to medium-term (6-12 mos). |
Cholesterol Management for Patients with a Cardiovascular Condition (HEDIS) | Percentage of members who had a cholesterol screening in the measurement year after an AMI discharge |
|
√ | 12-18 mos | ||
Left Ventricular Function (LVF) Assessment (AQA Measure) | Percentage of members with CHF who have the results of an LVF assessment recorded |
|
√ | 12-18 mos | ||
ACE Inhibitor or Angiotensin Receptor (ARB) Therapy (AQA Measure) | Percentage of members who have CHF and an LVSD who were prescribed ACEI or ARB |
|
√ | 6-12 mos | ||
Emergency Room (ER) Use | Percentage of CHF members with an ER visit for CHF in the past 12 mos |
|
√ | √ | 12 mos | Reducing ER visits can exert a significant impact on cost and quality of life. |
Physician Followup Post-ER Visit or Post-Hospitalization | Percentage of CHF members who followed up with a physician within 30 days after an ER visit or hospital admission |
|
√ | √ | 12-18 mos | |
Self-Management Goal | Percentage of members with CHF who have a self-management goal |
|
√ | √ | 6 mos | Self-management goals can be useful in gauging patient activation. |
Weight Self-Monitoring | Percentage of CHF members who monitor their weight daily |
|
√ | √ | 6-12 mos | This goal is useful in assessing patient activation. |
Influenza Vaccination | Percentage of all members with CHF who received a influenza vaccination within the last 12 mos |
|
√ | √ | 12 mos |
*Case data is collected by care managers during the process of delivering care management (e.g., through assessments, telephonic care management).